HUTCHMED initiated a registrational Phase III clinical trial of HMPL-760 in combination with R-GemOx versus placebo plus R-GemOx in patients with relapsed/refractory DLBCL in China, with the first patient dosed on March 20, 2026. The randomized, double-blind study plans to enroll approximately 240 patients and evaluates primary endpoints of PFS and OS.
Key takeaways
Initiated registrational Phase III trial (NCT07409428) of HMPL-760 + R-GemOx in relapsed/refractory DLBCL patients ineligible for transplantation
First patient received dose on 2026-03-20
Plans to enroll approximately 240 patients
Primary endpoints: investigator-assessed PFS and OS
Led by principal investigator Professor Weili Zhao of Ruijin Hospital